Header Logo

Connection

AMY B HEIMBERGER to Humans

Back to Details
This is a "connection" page, showing publications AMY B HEIMBERGER has written about Humans.
AMY B HEIMBERGER
Connection Strength
1.036
Humans
  1. Cancer-associated fibroblast-secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas. J Clin Invest. 2024 Feb 15; 134(4).
    View in: PubMed
    Score: 0.019
  2. The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions. JCI Insight. 2024 Jan 09; 9(1).
    View in: PubMed
    Score: 0.019
  3. cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res. 2022; 11:1010.
    View in: PubMed
    Score: 0.017
  4. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.017
  5. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology. 2022; 11(1):2062827.
    View in: PubMed
    Score: 0.017
  6. New Approaches to Glioblastoma. Annu Rev Med. 2022 01 27; 73:279-292.
    View in: PubMed
    Score: 0.016
  7. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.
    View in: PubMed
    Score: 0.016
  8. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells. 2021 08 09; 10(8).
    View in: PubMed
    Score: 0.016
  9. The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol. 2021 11; 18(11):729-744.
    View in: PubMed
    Score: 0.016
  10. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
    View in: PubMed
    Score: 0.015
  11. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.
    View in: PubMed
    Score: 0.015
  12. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712.
    View in: PubMed
    Score: 0.015
  13. Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients? Neuro Oncol. 2020 05 15; 22(5):590-591.
    View in: PubMed
    Score: 0.015
  14. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
    View in: PubMed
    Score: 0.015
  15. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.015
  16. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. Cancer Immunol Res. 2020 07; 8(7):952-965.
    View in: PubMed
    Score: 0.015
  17. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194.
    View in: PubMed
    Score: 0.014
  18. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function. J Neurooncol. 2019 Dec; 145(3):429-439.
    View in: PubMed
    Score: 0.014
  19. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
    View in: PubMed
    Score: 0.013
  20. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.
    View in: PubMed
    Score: 0.013
  21. Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma". Neuro Oncol. 2018 06 18; 20(7):1003-1004.
    View in: PubMed
    Score: 0.013
  22. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018 Sep; 139(3):713-720.
    View in: PubMed
    Score: 0.013
  23. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
    View in: PubMed
    Score: 0.013
  24. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057.
    View in: PubMed
    Score: 0.012
  25. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357.
    View in: PubMed
    Score: 0.012
  26. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017 03 11; 16(1):59.
    View in: PubMed
    Score: 0.012
  27. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2017 03 01; 19(3):372-382.
    View in: PubMed
    Score: 0.012
  28. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478.
    View in: PubMed
    Score: 0.011
  29. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
    View in: PubMed
    Score: 0.011
  30. Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol. 2016 07; 5(3):175-86.
    View in: PubMed
    Score: 0.011
  31. Principles of immunotherapy. Handb Clin Neurol. 2016; 134:163-81.
    View in: PubMed
    Score: 0.011
  32. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? Immunotherapy. 2016; 8(4):413-23.
    View in: PubMed
    Score: 0.011
  33. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
    View in: PubMed
    Score: 0.011
  34. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii9-vii14.
    View in: PubMed
    Score: 0.011
  35. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb; 18(2):195-205.
    View in: PubMed
    Score: 0.011
  36. The role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 2015 Jul; 123(3):385-94.
    View in: PubMed
    Score: 0.010
  37. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.
    View in: PubMed
    Score: 0.010
  38. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.010
  39. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013 Aug; 1(2):112-22.
    View in: PubMed
    Score: 0.009
  40. The controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013; 2013:285246.
    View in: PubMed
    Score: 0.009
  41. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26.
    View in: PubMed
    Score: 0.009
  42. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48.
    View in: PubMed
    Score: 0.009
  43. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.
    View in: PubMed
    Score: 0.008
  44. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011 Jul 15; 17(14):4642-9.
    View in: PubMed
    Score: 0.008
  45. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195.
    View in: PubMed
    Score: 0.008
  46. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan; 13(1):3-13.
    View in: PubMed
    Score: 0.008
  47. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.
    View in: PubMed
    Score: 0.008
  48. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.
    View in: PubMed
    Score: 0.008
  49. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010 Sep; 5(3):217-27.
    View in: PubMed
    Score: 0.007
  50. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25.
    View in: PubMed
    Score: 0.007
  51. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010 Jan 15; 16(2):461-73.
    View in: PubMed
    Score: 0.007
  52. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010 Jan; 9(1):67-78.
    View in: PubMed
    Score: 0.007
  53. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am. 2010 Jan; 21(1):125-37.
    View in: PubMed
    Score: 0.007
  54. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92.
    View in: PubMed
    Score: 0.007
  55. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug; 9(8):1087-98.
    View in: PubMed
    Score: 0.007
  56. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.
    View in: PubMed
    Score: 0.007
  57. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.
    View in: PubMed
    Score: 0.007
  58. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32.
    View in: PubMed
    Score: 0.007
  59. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008 Nov; 3(3):179-88.
    View in: PubMed
    Score: 0.007
  60. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008 Aug 15; 14(16):5166-72.
    View in: PubMed
    Score: 0.006
  61. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother. 2009 Feb; 58(2):259-70.
    View in: PubMed
    Score: 0.006
  62. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008 Feb; 10(1):98-103.
    View in: PubMed
    Score: 0.006
  63. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6.
    View in: PubMed
    Score: 0.006
  64. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 Jun 15; 13(12):3559-67.
    View in: PubMed
    Score: 0.006
  65. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008 Jan; 57(1):123-31.
    View in: PubMed
    Score: 0.006
  66. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79.
    View in: PubMed
    Score: 0.006
  67. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005 Oct; 5(5):777-90.
    View in: PubMed
    Score: 0.005
  68. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005 Feb 15; 11(4):1462-6.
    View in: PubMed
    Score: 0.005
  69. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 2005 Jan 01; 11(1):267-72.
    View in: PubMed
    Score: 0.005
  70. Mechanisms of action of rapamycin in gliomas. Neuro Oncol. 2005 Jan; 7(1):1-11.
    View in: PubMed
    Score: 0.005
  71. Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy. Proc Natl Acad Sci U S A. 2024 Feb 20; 121(8):e2306973121.
    View in: PubMed
    Score: 0.005
  72. Antigen-presenting B cells promote TCF-1+ PD1- stem-like CD8+ T-cell proliferation in glioblastoma. Front Immunol. 2023; 14:1295218.
    View in: PubMed
    Score: 0.005
  73. Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. J Clin Invest. 2023 Dec 15; 133(24).
    View in: PubMed
    Score: 0.005
  74. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun. 2023 11 02; 11(1):175.
    View in: PubMed
    Score: 0.005
  75. Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas. Nat Commun. 2023 10 07; 14(1):6279.
    View in: PubMed
    Score: 0.005
  76. Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. Neuro Oncol. 2023 08 03; 25(8):1415-1427.
    View in: PubMed
    Score: 0.005
  77. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. J Clin Invest. 2023 06 15; 133(12).
    View in: PubMed
    Score: 0.005
  78. Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Mol Cancer Res. 2023 05 01; 21(5):389-396.
    View in: PubMed
    Score: 0.004
  79. Aspirin and immunotherapy: a Faustian bargain? J Clin Invest. 2023 05 01; 133(9).
    View in: PubMed
    Score: 0.004
  80. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023 03 22; 14(1):1566.
    View in: PubMed
    Score: 0.004
  81. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood. 2023 03 16; 141(11):1322-1336.
    View in: PubMed
    Score: 0.004
  82. Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. 2023 02 28; 42(2):112127.
    View in: PubMed
    Score: 0.004
  83. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023 01 17; 133(2).
    View in: PubMed
    Score: 0.004
  84. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest. 2023 01 03; 133(1).
    View in: PubMed
    Score: 0.004
  85. Biphasic malignant meningioma: a comparative genomic hybridization study. Clin Neuropathol. 2002 Nov-Dec; 21(6):258-64.
    View in: PubMed
    Score: 0.004
  86. CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. Int J Cancer. 2023 02 15; 152(4):713-724.
    View in: PubMed
    Score: 0.004
  87. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. Cytokine Growth Factor Rev. 2023 02; 69:73-79.
    View in: PubMed
    Score: 0.004
  88. Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight. 2022 06 22; 7(12).
    View in: PubMed
    Score: 0.004
  89. Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. Front Immunol. 2022; 13:907605.
    View in: PubMed
    Score: 0.004
  90. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
    View in: PubMed
    Score: 0.004
  91. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022 10; 8(10):839-854.
    View in: PubMed
    Score: 0.004
  92. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
    View in: PubMed
    Score: 0.004
  93. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell. 2022 05 09; 40(5):439-440.
    View in: PubMed
    Score: 0.004
  94. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.
    View in: PubMed
    Score: 0.004
  95. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593.
    View in: PubMed
    Score: 0.004
  96. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int J Mol Sci. 2021 Dec 13; 22(24).
    View in: PubMed
    Score: 0.004
  97. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2021 12; 2(12):1372-1386.
    View in: PubMed
    Score: 0.004
  98. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021 Oct 27; 13(617):eabe6201.
    View in: PubMed
    Score: 0.004
  99. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
    View in: PubMed
    Score: 0.004
  100. Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).
    View in: PubMed
    Score: 0.004
  101. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. BMC Neurol. 2021 Jun 23; 21(1):231.
    View in: PubMed
    Score: 0.004
  102. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
    View in: PubMed
    Score: 0.004
  103. Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms. Trends Immunol. 2021 04; 42(4):280-292.
    View in: PubMed
    Score: 0.004
  104. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 2021 02 25; 23(2):284-294.
    View in: PubMed
    Score: 0.004
  105. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. 2021 01; 7(5).
    View in: PubMed
    Score: 0.004
  106. Qki is an essential regulator of microglial phagocytosis in demyelination. J Exp Med. 2021 01 04; 218(1).
    View in: PubMed
    Score: 0.004
  107. Targeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am. 2020 Oct; 31(4):641-649.
    View in: PubMed
    Score: 0.004
  108. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.004
  109. Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020 08 26; 21(1):216.
    View in: PubMed
    Score: 0.004
  110. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO J. 2020 08 03; 39(15):e103790.
    View in: PubMed
    Score: 0.004
  111. CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clin Cancer Res. 2020 08 15; 26(16):4390-4401.
    View in: PubMed
    Score: 0.004
  112. Mature myelin maintenance requires Qki to coactivate PPAR?-RXRa-mediated lipid metabolism. J Clin Invest. 2020 05 01; 130(5):2220-2236.
    View in: PubMed
    Score: 0.004
  113. Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2021 Jan; 151(1):65-73.
    View in: PubMed
    Score: 0.004
  114. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell. 2020 02 10; 37(2):243-257.e7.
    View in: PubMed
    Score: 0.004
  115. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020 01 01; 86(1):112-121.
    View in: PubMed
    Score: 0.004
  116. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
    View in: PubMed
    Score: 0.004
  117. Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opin Ther Targets. 2019 08; 23(8):647-649.
    View in: PubMed
    Score: 0.003
  118. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019 May; 142(3):499-509.
    View in: PubMed
    Score: 0.003
  119. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 03 01; 111(3):292-300.
    View in: PubMed
    Score: 0.003
  120. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 01 25; 10(1):448.
    View in: PubMed
    Score: 0.003
  121. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett. 2018 10 01; 433:176-185.
    View in: PubMed
    Score: 0.003
  122. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep; 139(2):469-478.
    View in: PubMed
    Score: 0.003
  123. Identification of metabolites in plasma for predicting survival in glioblastoma. Mol Carcinog. 2018 08; 57(8):1078-1084.
    View in: PubMed
    Score: 0.003
  124. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219.
    View in: PubMed
    Score: 0.003
  125. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018 Jan; 57(1):137-141.
    View in: PubMed
    Score: 0.003
  126. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol. 2018 Jan; 136(1):33-39.
    View in: PubMed
    Score: 0.003
  127. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017 07 10; 32(1):42-56.e6.
    View in: PubMed
    Score: 0.003
  128. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
    View in: PubMed
    Score: 0.003
  129. Immune Checkpoint Inhibitors for Brain Metastases. Curr Oncol Rep. 2017 Jun; 19(6):38.
    View in: PubMed
    Score: 0.003
  130. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget. 2016 Nov 01; 7(44):72021-72032.
    View in: PubMed
    Score: 0.003
  131. Interrogating Metabolism in Brain Cancer. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):687-703.
    View in: PubMed
    Score: 0.003
  132. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother. 2016 06; 39(5):205-17.
    View in: PubMed
    Score: 0.003
  133. miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016 07 15; 76(14):4293-304.
    View in: PubMed
    Score: 0.003
  134. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016 Apr 12; 7(15):20486-95.
    View in: PubMed
    Score: 0.003
  135. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 2015 Sep 01; 75(17):3505-18.
    View in: PubMed
    Score: 0.003
  136. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.003
  137. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015 Jun 01; 75(11):2337-48.
    View in: PubMed
    Score: 0.003
  138. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
    View in: PubMed
    Score: 0.003
  139. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014 Nov 15; 20(22):5620-9.
    View in: PubMed
    Score: 0.002
  140. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii20-5.
    View in: PubMed
    Score: 0.002
  141. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol. 2016 07 03; 35(4):325-339.
    View in: PubMed
    Score: 0.002
  142. Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma. Cancer Cell. 2013 Sep 09; 24(3):331-46.
    View in: PubMed
    Score: 0.002
  143. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother. 2013 Jun; 62(6):983-7.
    View in: PubMed
    Score: 0.002
  144. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013 Apr; 118(4):873-883.
    View in: PubMed
    Score: 0.002
  145. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.
    View in: PubMed
    Score: 0.002
  146. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):246-55.
    View in: PubMed
    Score: 0.002
  147. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.
    View in: PubMed
    Score: 0.002
  148. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9.
    View in: PubMed
    Score: 0.002
  149. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010 Jan; 21(1):95-109.
    View in: PubMed
    Score: 0.002
  150. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009 Oct; 19(4):713-23.
    View in: PubMed
    Score: 0.002
  151. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9.
    View in: PubMed
    Score: 0.002
  152. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009 Aug 01; 125(3):680-7.
    View in: PubMed
    Score: 0.002
  153. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009 Jun 17; 4(6):e5947.
    View in: PubMed
    Score: 0.002
  154. Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009 May; 64(5):836-45; discussion 345-6.
    View in: PubMed
    Score: 0.002
  155. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30; 339(1):74-81.
    View in: PubMed
    Score: 0.002
  156. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008 Oct; 20(5):267-75.
    View in: PubMed
    Score: 0.002
  157. Central nervous system cancers. J Natl Compr Canc Netw. 2008 May; 6(5):456-504.
    View in: PubMed
    Score: 0.002
  158. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 2007 Nov; 17(11):1586-95.
    View in: PubMed
    Score: 0.002
  159. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007 Jun 01; 25(16):2288-94.
    View in: PubMed
    Score: 0.001
  160. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006 Jul 01; 12(13):3935-41.
    View in: PubMed
    Score: 0.001
  161. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):644-90.
    View in: PubMed
    Score: 0.001
  162. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5.
    View in: PubMed
    Score: 0.001
  163. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003 Dec 15; 9(17):6560-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.